RESEARCH STUDY: PROJECTING THE IMPACT OF DELAYED ACCESS TO TRIKAFTA
In August 2020, Cystic Fibrosis Canada shared news of a game-changing study published showing the dramatic life-saving benefits of the breakthrough cystic fibrosis modulator drug, Trikafta.
The study examines the potential health outcomes for the Canadian cystic fibrosis population by 2030 assessing three scenarios: getting access to the drug in 2021, getting access to the drug in 2025 and not getting access at all.
The study shows that early introduction of Trikafta in 2021 would result in life-changing health improvements by 2030 in comparison to no drug available, including:
The estimated median age of survival for a child born with CF would increase by 9.2 years
60% fewer people living with severe lung disease due to cystic fibrosis
15% fewer deaths
18% increase in people with mild lung disease
19% fewer hospitalizations or home intravenous courses for chest infections
A reduction in the number of transplants that are required for severe lung disease